

# Ethnic diversity in presentation and outcome of Waldenström macroglobulinemia and IgM monoclonal gammopathy of clinical significance in the United Kingdom

Jahanzaib Khwaja, Nicole Japzon, Maria Gabriel, Oliver Tomkins, Jindriska Lindsay, Charalampia Kyriakou, Ashutosh Wechalekar and Shirley D'Sa

University College London Hospital, London, UK

Correspondence:

J. KHWAJA - j.khwaja@nhs.net

<https://doi.org/10.3324/haematol.2024.285420>

**Supplementary 1. Ethnic categories (UK Census):**

<b>Ethnic categories</b>	
Asian or Asian British	<ul style="list-style-type: none"><li>• Indian</li><li>• Pakistani</li><li>• Bangladeshi</li><li>• Chinese</li><li>• Any other Asian background</li></ul>
Black, Black British, Caribbean or African	<ul style="list-style-type: none"><li>• Caribbean</li><li>• African</li><li>• Any other Black, Black British, or Caribbean background</li></ul>
Mixed or multiple ethnic groups	<ul style="list-style-type: none"><li>• White and Black Caribbean</li><li>• White and Black African</li><li>• White and Asian</li><li>• Any other Mixed or multiple ethnic background</li></ul>
White	<ul style="list-style-type: none"><li>• English, Welsh, Scottish, Northern Irish or British</li><li>• Irish</li><li>• Gypsy or Irish Traveller</li><li>• Roma</li><li>• Any other White background</li></ul>
Other ethnic group	<ul style="list-style-type: none"><li>• Arab</li><li>• Any other ethnic group</li></ul>

**Supplementary table 2. First-line therapy indications**

<b>Indications for treatment</b>	<b>Total</b>	<b>White</b>	<b>Asian</b>	<b>Black<sup>~</sup></b>	<b>Other/mixed<sup>#</sup></b>
Bone marrow failure	120	107	10	0	3
M-protein related	112	101	8	0	3
Lymphoma-related	107	94	8	3	2

Bone marrow failure (haemoglobin <100 g/L, platelets <100 × 10<sup>9</sup>/L or neutrophils <1 × 10<sup>9</sup>/L); M-protein related (hyperviscosity, autoimmune, IgM-associated disorder); lymphoma-related (bulky or symptomatic lymphadenopathy/ organomegaly, B-symptoms).

<sup>~</sup>1 patient unknown indication <sup>#</sup>4 patients unknown indication

**Supplementary table 3. First-line therapy**

<b>Therapy</b>	<b>Total</b>	<b>White</b>	<b>Asian</b>	<b>Black</b>	<b>Other/mixed</b>
Bendamustine-rituximab	102	89	5	2	6
Dexamethasone-rituximab-cyclophosphamide	76	70	4	0	2
BTKi	15	15	0	0	0
Single agent rituximab	27	25	2	0	0
Bortezomib-based combination	13	11	2	0	0
Methotrexate-cytarabine based combination	12	10	1	1	0
RCHOP	11	11	0	1	0
Chlorambucil	8	9	0	0	0
Other	19	15	2	0	2

RCHOP, Rituximab-cyclophosphamide-doxorubicin-vincristine-prednisolone